328 related articles for article (PubMed ID: 28824055)
21. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
Tang Y; Massey D; Zhong NS
Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149
[TBL] [Abstract][Full Text] [Related]
22. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
Ferguson GT; Karpel J; Bennett N; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
NPJ Prim Care Respir Med; 2017 Feb; 27(1):7. PubMed ID: 28154373
[TBL] [Abstract][Full Text] [Related]
23. Comparison of clinical efficacy and satisfaction of Tiotropium via Respimat® administration with and without a spacer in patient with Chronic Obstructive Pulmonary Disease: A single centre experience.
Mohamed Faisal AH; Hemalatha M; Mas Fazlin MJ; Boon Hau N; Nik Nuratiqah NA; Andrea Ban YL
Med J Malaysia; 2022 Jul; 77(4):481-487. PubMed ID: 35902939
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
[TBL] [Abstract][Full Text] [Related]
25. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial.
Watz H; Mailänder C; May C; Baier M; Kirsten AM
Pulm Pharmacol Ther; 2017 Feb; 42():13-20. PubMed ID: 27940287
[TBL] [Abstract][Full Text] [Related]
26. Study Design of VESUTO
Ichinose M; Minakata Y; Motegi T; Ueki J; Seki T; Anzai T; Takizawa A; Grönke L; Hirata K
Adv Ther; 2017 Jul; 34(7):1622-1635. PubMed ID: 28537001
[TBL] [Abstract][Full Text] [Related]
27. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease.
Zhou Y; Zhong NS; Li X; Chen S; Zheng J; Zhao D; Yao W; Zhi R; Wei L; He B; Zhang X; Yang C; Li Y; Li F; Du J; Gui J; Hu B; Bai C; Huang P; Chen G; Xu Y; Wang C; Liang B; Li Y; Hu G; Tan H; Ye X; Ma X; Chen Y; Hu X; Tian J; Zhu X; Shi Z; Du X; Li M; Liu S; Yu R; Zhao J; Ma Q; Xie C; Li X; Chen T; Lin Y; Zeng L; Ye C; Ye W; Luo X; Zeng L; Yu S; Guan WJ; Ran P
N Engl J Med; 2017 Sep; 377(10):923-935. PubMed ID: 28877027
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy and safety of tiotropium Respimat in the treatment of chronic obstructive pulmonary disease: systematic review].
Cai HD; Hou J; Lyu YN; Xiong L; Lu MZ; Wu SL
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Aug; 40(8):596-603. PubMed ID: 28810313
[No Abstract] [Full Text] [Related]
29. [The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease].
Ma J; Zhou Z; Tang Y; Zhong N
Zhonghua Nei Ke Za Zhi; 2014 Dec; 53(12):964-8. PubMed ID: 25623564
[TBL] [Abstract][Full Text] [Related]
30. Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma.
Beeh KM; Moroni-Zentgraf P; Ablinger O; Hollaenderova Z; Unseld A; Engel M; Korn S
Respir Res; 2014 Jun; 15(1):61. PubMed ID: 24890738
[TBL] [Abstract][Full Text] [Related]
31. Effects of inhaled tiotropium plus transdermal tulobuterol versus tiotropium alone on impulse oscillation system (IOS)-assessed measures of peripheral airway resistance and reactance, lung function and quality of life in patients with COPD: a randomized crossover study.
Abe T; Setoguchi Y; Kono Y; Togashi Y; Sugiyama S; Tanakadate M; Soeda S; Nakai M; Sugiyama N; Fujiwara A; Yamaguchi K; Yamaguchi A; Kurita N
Pulm Pharmacol Ther; 2011 Oct; 24(5):617-24. PubMed ID: 21689775
[TBL] [Abstract][Full Text] [Related]
32. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
[TBL] [Abstract][Full Text] [Related]
33. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR
Wise RA; Calverley PM; Carter K; Clerisme-Beaty E; Metzdorf N; Anzueto A
Int J Chron Obstruct Pulmon Dis; 2018; 13():605-616. PubMed ID: 29497289
[TBL] [Abstract][Full Text] [Related]
34. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.
Vogelberg C; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Hamelmann E; Engel M; Szefler S
Respir Res; 2015 Feb; 16(1):20. PubMed ID: 25851298
[TBL] [Abstract][Full Text] [Related]
35. Tiotropium Respimat inhaler and the risk of death in COPD.
Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
[TBL] [Abstract][Full Text] [Related]
36. Comparative Effectiveness of Two Tiotropium Formulations: A Retrospective Cohort Study.
Spila-Alegiani S; Trotta F; Da Cas R; Rossi M; Venegoni M; Traversa G
COPD; 2018 Oct; 15(5):418-423. PubMed ID: 30822243
[TBL] [Abstract][Full Text] [Related]
37. [Spiolto Respimat® : tiotropium-olodaterol fixed combination for therapy of chronic obstructive pulmonary disease (COPD)].
Cataldo D
Rev Med Liege; 2016 Jun; 71(6):308-313. PubMed ID: 28383865
[TBL] [Abstract][Full Text] [Related]
38. [The efficacy and safety of tiotropium/olodaterol fixed-dose combination in Chinese patients with chronic obstructive pulmonary disease: a pooled subgroup analysis of TONADO 1+2].
Bai CX; Tang Y; Xin JB; Li YL; Li ZK; Kang J; Huang JA; Xiao W; Wen ZG; Fu XH; He B; Liu CT; Chen P
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Nov; 42(11):838-844. PubMed ID: 31694094
[No Abstract] [Full Text] [Related]
39. Comparison of the rapid effects of single inhalations of formoterol and tiotropium bromide on respiratory function and COPD symptoms in a randomized crossover study.
Ohbayashi H
Respir Investig; 2017 Nov; 55(6):348-356. PubMed ID: 29153415
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
